Richard Michael Simonson

US Patent:

7993670, Aug 9, 2011

Filed:

Aug 20, 2003

Appl. No.:

10/525323

Inventors:

Richard M. Simonson - New York NY, US
Theodore McAllister - San Antonio TX, US
Richard R. Suchanec - Newark DE, US
Daniel A. White - La Grange TX, US

Assignee:

General Wound Kare, Inc. - New York NY

International Classification:

A61K 9/70
A61K 31/44
A61K 31/47
A61K 31/135
A41D 19/00
A61F 13/02

US Classification:

424443, 514283, 514297, 514310, 514649, 427 23, 427 231

Abstract:

A germicidal absorptive material for use in surgical packings, wound bandages, sanitary tampons and bed sore prevention and/or treatment uses is provided by a foam-like matrix of hydrophilic polyurethane polymer to which application-specific loads of a germicidal disinfectant dye have been made. Polyurethane polymer of various densities and thicknesses exhibits an exceptional ability to absorb different levels of a number of disinfectant dyes, both basic and acidic, such as gentian violet and methylene blue, respectively. The relationship between dye-load and application-specific uses permits a totally-bound gentian violet pad to be used as a conventional bandage or pad on a surface wound with the capability of preventing the incursion of external pathogens from entering the wound through the pad, where the pathogens are killed by the bound-dye. The wound exudate is absorbed safely by the pad, where wound-originating pathogens are also killed. When the loaded dye's concentration is saturated by exceeding the bound-dye limit, the limited free-dye is available to be delivered to the wound, particularly deep wounds, to rapidly kill pathogens in the wound.

US Patent:

20210290590, Sep 23, 2021

Filed:

Mar 12, 2021

Appl. No.:

17/199831

Inventors:

- Co Cork, IE
Wing CHOW - Belle Mead NJ, US
Keith J. DUNN - Philadelphia PA, US
Donghan LUO - Randolph NJ, US
Richard E. NETTLES - New Hope PA, US
Richard Bruce SIMONSON - Southampton PA, US

International Classification:

A61K 31/34
A61K 9/00
A61K 31/5377
A61K 31/513
A61K 31/675
A61P 31/18

Abstract:

The disclosure is directed to methods of treating humans diagnosed with an HIV infection and who experience weight gain while being treated with an integrase inhibitor regimen, as well as a novel HIV inhibitor regime for use in the treatment of those humans.